TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05429528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit Tax
Description: This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit Tiered Tax
Description: This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
Study: NCT06452134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 MG Oral Tablet
Description: Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
Study: NCT05263700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: PET with the investigational tracer 68Ga-FAPI-46 with accompanying low-dose CT for anatomical localisation
Study: NCT05401955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: An adapted physical exercise protocol
Study: NCT06147648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules
Description: Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
Study: NCT05451524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia prevention program
Description: Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
Study: NCT04939441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Description: Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
Study: NCT06341452

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control
Description: Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control
Description: Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
Study: NCT06502067

Intervention type: DRUG
Group type: OTHER
Intervention: Analgesia mangement group A,B
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Study: NCT05451524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education
Description: Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
Study: NCT04048434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb
Description: extracorporeal cytokine adsorption
Study: NCT06502067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia mangement group A,B
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Study: NCT05951335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: m-Health Transition Care Program
Description: The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
Study: NCT05297513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ActiveMatrix
Description: All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
Study: NCT04678947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baxter Retching Faces (BARF) scale
Description: * Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea).
Study: NCT05247281

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Culture-based treatment
Description: Medications to treat prosthetic joint infection will be chosen based on results of traditional cultures alone

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Next Generation Sequencing (NGS) with Culture
Description: Medications to treat prosthetic joint infection will be chosen based results of NGS and culture
Study: NCT04970628

Intervention type: OTHER
Intervention: Medical records collection
Description: Patient's medical records before and after surgery.

Intervention type: OTHER
Intervention: Medical records collection
Description: Patient's medical records before and after surgery.
Study: NCT05902338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music).
Study: NCT05725551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger Puppet group
Description: During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon group
Description: An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale.
Study: NCT05926830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonovein Treatment
Description: The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
Study: NCT05795192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day
Study: NCT06035666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Your World
Description: Your World consists of a vitality session and use of the Your World app
Study: NCT05787626

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: manipulation
Description: miofascial technique in diaphragmatic region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manipulation
Description: miofascial technique in diaphragmatic region
Study: NCT03772717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation (nVNS)
Description: The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
Study: NCT05546437

Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Ion Endoluminal dye marking procedure for pulmonary nodule
Study: NCT06035666

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control app
Description: Control app, no effect on stress/vitality
Study: NCT06387134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifei Xiaoji Wan
Description: The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment with Western medicine
Description: Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021.
Study: NCT06381024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote patient monitoring
Description: Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken.
Study: NCT04932564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide tablet
Description: Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
Study: NCT06372847

Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglossal nerve stimulation implant
Description: The hypoglossal nerve stimulation (HNS) implantation and therapy will be performed according to the standard clinical practice without additional procedures. Information about the surgical procedure will be collected. HNS implant information and settings will be collected throughout the study until the last study measurement (one year follow-up PSG and DISE) for that patient. No additional measures or interventions as part of the research project will be performed during implantation or treatment with HNS.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Polysomnography
Description: A PSG at one-year follow-up is part of the standard follow-up pathway in patients receiving HNS therapy. In this study, PSG data will be collected from both baseline and one-year follow-up PSGs to assess treatment effect. Additionally, PSG data will be used for non-invasive prediction of the site and pattern of collapse using a novel, validated tool developed at our research group.
Study: NCT05180448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Standard Behavioral Weight Loss Treatment (remotely delivered)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Standard Behavioral Weight Loss Treatment (remotely delivered)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Standard Behavioral Weight Loss Treatment (remotely delivered)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Standard Behavioral Weight Loss Treatment (remotely delivered)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Standard Behavioral Weight Loss Treatment (remotely delivered)
Study: NCT05795192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day
Study: NCT06372847

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Drug-induced sleep endoscopy (DISE)
Description: Drug-induced sleep endoscopy (DISE) is the clinical standard diagnostic test to assess site, pattern and degree of upper-airway collapse in OSA. Baseline DISE is part of the standard clinical pathway for HNS eligibility.~In this study, DISE data will be collected from routine baseline DISE without any additional procedures for the patient. They will undergo an additional DISE at one-year follow-up to assess the effect of HNS-therapy on site, pattern and degree of collapse. Both DISEs will be performed according to routine clinical practice in the operating theatre. Sleep will be induced using 1.5 mg bolus injection midazolam and target-controlled propofol infusion (2.0 - 3.0 μg). A flexible fiberoptic nasopharyngoscope will be transnasally inserted. Site, pattern and degree of collapse will be assessed using a standardized scoring system. Other maneuvers, including chin-lift, the use of a simulation bite or lateral position of the head will be performed according to clinical practice.
Study: NCT05795192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day
Study: NCT05180448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Standard Behavioral Weight Loss Treatment (remotely delivered)
Study: NCT06370741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stretching with/without device
Description: Participants will be divided into two groups: Achilles tendon stretching and plantar fascia specific stretching. Within these two groups, participants will stretch their dominant side with the help of the designed tool. On the non-dominant side, the Achilles tendon group will complete the Achilles tendon stretching without a tool and the plantar fascia-specific stretching group will complete the self plantar fascia stretching exercise. Each stretching exercise will be performed for 10 seconds and 10 repetitions 3 days a week for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching with/without device
Description: Participants will be divided into two groups: Achilles tendon stretching and plantar fascia specific stretching. Within these two groups, participants will stretch their dominant side with the help of the designed tool. On the non-dominant side, the Achilles tendon group will complete the Achilles tendon stretching without a tool and the plantar fascia-specific stretching group will complete the self plantar fascia stretching exercise. Each stretching exercise will be performed for 10 seconds and 10 repetitions 3 days a week for 2 weeks.
Study: NCT06499532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitoring and Surgical removal of mandibular impacted wisdom teeth, using Gow-Gates anesthesia technique
Description: The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using Gow-Gates anesthesia technique. Patients were monitored for TCR during the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitoring and Surgical removal of mandibular impacted wisdom teeth, using Gow-Gates anesthesia technique
Description: The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using Gow-Gates anesthesia technique. Patients were monitored for TCR during the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitoring and Surgical removal of mandibular impacted wisdom teeth, using inferior alveolar nerve block anesthesia technique
Description: The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using inferior alveolar nerve block anesthesia technique and supplemental anesthesia (buccal- mylohyoid). Patients were monitored for TCR during the procedure.
Study: NCT05701176

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET scan
Description: \[18F\]F-AraG PET scans are performed to assess the accumulation of activated T-cells in the tumour and healthy tissue.
Study: NCT05795192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day
Study: NCT05555199

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-nanocolloid
Description: Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
Study: NCT05381740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel rTMS Approach
Description: Participants in this arm will receive rTMS-based facilitation of the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. High-frequency rTMS (5Hz) will be delivered using 42 10 second trains of 50 pulses each (total 2100 pulses) for a period of 22 minutes. Immediately after the completion of rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Approach
Description: Participants in this arm will receive sham rTMS given over the contralesional higher motor cortices located in the non-stroke hemisphere before the start of each rehabilitation session. Immediately after the completion of sham rTMS, participants will undergo therapist-guided upper limb therapy for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks for a total of 12 sessions.
Study: NCT05555199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
Study: NCT05795192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking Placebo orally once a day
Study: NCT05542004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Principles
Description: The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
Study: NCT05296785

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intramedullary nail with Limb Reconstruction System
Description: bone transport by Limb Reconstruction System over intramedullary nail on fracture tibia